Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Gompel

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Maturitas|May 11, 2005
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapySven O Skouby, Farook Al-Azzawi, David Barlow, et al.
Virchows Archiv : an International Journal of Pathology|August 25, 2017
Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcomeMikaël Agopiantz, Patricia Forgez, Jean-Matthieu Casse, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 2014
New NOBOX mutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expressionJustine Bouilly, Florence Roucher-Boulez, Anne Gompel, et al.
Carcinogenesis|November 22, 2005
Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomasFrédérique Souazé, Véronique Viardot-Foucault, Nicolas Roullet, et al.
Journal of the National Cancer Institute|December 24, 2013
Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational studySamuel Shapiro, Tobie J deVilliers, Amos Pines, et al.
Annales D'Endocrinologie|October 20, 2012
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of EndocrinologyPierre Gourdy, Anne Bachelot, Sophie Catteau-Jonard, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 12, 2025
Contraception and risk factors in young women with myocardial infarction: The WAMIF studyAnne Gompel, Geneviève Plu-Bureau, Najiba Lahlou, et al.
Archives of Cardiovascular Diseases|January 15, 2023
Myocardial infarction in women under 50: Possible implication of clonal haematopoiesis of indetermined potentialSimon Soudet, Guillaume Jedraszak, Ludovic Drouet, et al.
Cancer Letters|December 25, 2018
Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibodyZherui Wu, Ludovic Fournel, Nicolas Stadler, et al.
Oncotarget|June 2, 2016
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutationsLaudine Communal, Myriam Vilasco, Justine Hugon-Rodin, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Maturitas|May 11, 2005
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapySven O Skouby, Farook Al-Azzawi, David Barlow, et al.
Virchows Archiv : an International Journal of Pathology|August 25, 2017
Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcomeMikaël Agopiantz, Patricia Forgez, Jean-Matthieu Casse, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 2014
New NOBOX mutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expressionJustine Bouilly, Florence Roucher-Boulez, Anne Gompel, et al.
Carcinogenesis|November 22, 2005
Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomasFrédérique Souazé, Véronique Viardot-Foucault, Nicolas Roullet, et al.
Journal of the National Cancer Institute|December 24, 2013
Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational studySamuel Shapiro, Tobie J deVilliers, Amos Pines, et al.
Annales D'Endocrinologie|October 20, 2012
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of EndocrinologyPierre Gourdy, Anne Bachelot, Sophie Catteau-Jonard, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 12, 2025
Contraception and risk factors in young women with myocardial infarction: The WAMIF studyAnne Gompel, Geneviève Plu-Bureau, Najiba Lahlou, et al.
Archives of Cardiovascular Diseases|January 15, 2023
Myocardial infarction in women under 50: Possible implication of clonal haematopoiesis of indetermined potentialSimon Soudet, Guillaume Jedraszak, Ludovic Drouet, et al.
Cancer Letters|December 25, 2018
Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibodyZherui Wu, Ludovic Fournel, Nicolas Stadler, et al.
Oncotarget|June 2, 2016
Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutationsLaudine Communal, Myriam Vilasco, Justine Hugon-Rodin, et al.
Pageof 13